Abstract
Introduction Tumor mutational burden (TMB) has been proposed as a novel predictive biomarker for the stratification of patients undergoing immune-checkpoint inhibitor (ICI) treatment in non-small cell lung cancer (NSCLC) patients. The assessment of TMB has recently been established using large targeted sequencing panels and numerous studies are ongoing to harmonize the TMB assessment. However, usually "correlation" has been used to evaluate the association between the respective panels and we hypothesized that correlation might overestimate the comparability especially in lower TMB values, thus limiting the joint analysis of targeted sequencing panels for the assessment of TMB. Methods Thirty NSCLC samples from patients undergoing ICI treatment were consecutively sequenced using three large targeted sequencing panels: FoundationOne, Oncomine TML and QiaSeq TMB, respectively. TMB values were compared in the whole patient population and in a subset of patients where the TMB assessed by FoundationOne was between 5-25 mutations/Mb. Prediction of durable clinical benefit (DCB; >6 months no progression) was assessed using receiver operator characteristics and optimal cut-off values were calculated using Youden's J. Results Correlation between the targeted sequencing panels was strong in the whole patient population between the three panels (R2 > 0.79) but was dramatically reduced in the subset of patients with TMB 5-25 mutations/Mb. All panels were able to predict DCB in the TMB high population. Conclusions Assessment of TMB using the three targeted sequencing panels was possible and predictive of response to ICI treatment but "correlation" was an inappropriate measurement to assess the association between the respective panels.
Competing Interest Statement
Simon Heeke has received honoraria from Qiagen and Boehringer Ingelheim. Marius Ilié has received honoraria from Roche, Merck & co, AstraZeneca, BMS and Boehringer Ingelheim. Paul Hofman has received honoraria from Roche, AstraZeneca, BMS, Novartis, Merck, MSD, Bayer, Qiagen, Thermo Fisher and Biocartis. All other authors have no conflict of interest to declare.
Funding Statement
This work has been partially funded by the Canceropôle PACA, the Ligue Départemental 06 de Lutte contre le cancer, the Conseil Départemental 06, and the French government through the LABEX SIGNALIFE program with the reference number ANR-11-LABX-0028-01 and the UCIJEDI program, with the reference number ANR-15-IDEX-01, as well as by the French Association for Cancer Research (ARC) by the Cancair Genexposomics grant. The funding organizations had no role in the design and conduct of the study.
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be made accessible upon justified request.
